Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scientific Inc. (MLSS) is described in its public disclosures as a technology-focused medical research and development company that patents, designs and develops computerized injection technologies and instruments for medical, dental and cosmetic applications. The company’s news flow centers on its computerized drug delivery instruments, which are designed to provide painless and precise injections using its DPS Dynamic Pressure Sensing Technology® platform.
News updates commonly cover developments in Milestone Scientific’s dental segment, including expansion of direct sales programs in North America, new international registrations for the STA® Single Tooth Anesthesia System, and initiatives such as The Wand® Ambassador Program. That program uses experienced dental professionals to share real-world clinical insights and workflow considerations to support broader adoption of The Wand STA System.
In the medical segment, news items highlight the CompuFlo® technology and the CompuFlo Epidural System, including growing utilization of CompuFlo disposables, interest from hospitals and international distributors, and progress on reimbursement strategies. Milestone Scientific reports milestones such as Medicare Part B payment-rate assignments under CPT® code 0777T in several jurisdictions and early activity from commercial insurers, which it views as important for adoption in interventional pain management and spine intervention markets.
Other recurring themes in Milestone Scientific’s news include quarterly financial results, cost-management and operational transformation efforts, leadership appointments, board changes, and updates on NYSE American listing compliance matters. Investors and observers can use this news stream to follow the company’s commercial initiatives in dental and medical markets, its reimbursement and payer-access efforts, and its corporate and governance developments over time.
Milestone Scientific (NYSE: MLSS) announced a conference call scheduled for November 15, 2021, at 11:00 A.M. ET. The call will address the company’s third-quarter financial results for the period ending September 30, 2021, alongside updates on corporate progress and developments. Investors can access the call via telephone or a webcast. Additionally, an audio replay will be available until November 29, 2021. Milestone Scientific specializes in computerized drug delivery systems aimed at improving injection precision and patient comfort.
On October 18, 2021, Milestone Scientific (NYSE:MLSS) announced that CEO Arjan Haverhals will present at the Dawson James Securities Small Cap Growth Conference on October 21, 2021. The presentation is scheduled for 1:10 PM Eastern Time, with additional one-on-one meetings for qualified investors planned throughout the event. Interested parties can access the live webcast and archived recordings through the company's investor relations section. Milestone Scientific specializes in computerized drug delivery systems aimed at improving patient comfort during injections.
Milestone Scientific Inc. (NYSE:MLSS) has expanded its international presence by signing new distribution agreements in Canada, Slovenia, and the UAE for its CompuFlo Epidural Instrument. The partnerships aim to enhance women's health by providing safer pain relief during childbirth. Additionally, increased usage of the device at a leading German hospital showcases rising interest and demand.
Milestone Scientific Inc. (NYSE: MLSS) announced its participation in the Fall Harvest - Best Ideas from the Buy-Side conference, running from October 5-8, 2021. CEO Arjan Haverhals will present on October 6, 2021, at 9:30 AM ET, with the presentation available for live streaming and replay. This virtual conference features 36 top investment ideas recommended by qualified institutional investors. Milestone Scientific specializes in computerized drug delivery instruments aimed at enhancing patient comfort and safety during injections.
Milestone Scientific (NYSE:MLSS) has announced that Memorial Regional Hospital in Florida has begun utilizing its CompuFlo Epidural Instrument. This approval allows Milestone to supply both the CompuFlo and CathCheck Verification System disposables across the Memorial Healthcare System network. This milestone follows significant due diligence and expands Milestone’s sales pipeline. Clinical data supports that these instruments enhance safety and efficiency in epidural procedures, potentially reducing complications and costs for healthcare providers.
Milestone Scientific (MLSS) reported a significant revenue increase of 1,329% for Q2 2021, totaling $2.4 million, driven by a recovery in the dental sector. Gross profit rose to $1.4 million, with a reduced operating loss of $(2.9) million compared to $(3.2) million in Q2 2020. The company noted a healthy balance sheet with approximately $16 million in cash. CEO Arjan Haverhals expressed optimism about growth prospects, driven by new sales initiatives and expanding the sales force and international distribution.
Milestone Scientific (NYSE American: MLSS) announced a conference call on August 16, 2021, at 11:00 A.M. ET to discuss its second-quarter financial results and corporate developments. The call can be accessed via phone or webcast. An audio replay will be available until August 30, 2021. Milestone Scientific specializes in innovative drug delivery technologies, particularly for painless injections using its proprietary DPS Dynamic Pressure Sensing technology® for various medical applications. For further details, visit their website.
Milestone Scientific Inc. (NYSE:MLSS) announced that the University of Texas Medical Branch (UTMB) Health Clear Lake Campus Hospital has begun utilizing the CompuFlo® Epidural Instrument. This development follows the successful implementation at the UTMB Health Galveston Campus. CEO Arjan Haverhals noted the growing interest in their technology and the positive feedback from anesthesiologists. Milestone's innovative technology aims to enhance the precision and comfort of injections, marking a significant step in their expansion within the UTMB Health network.
Milestone Scientific (NYSE: MLSS) announced the expansion of its medical sales team, appointing Chet Trechock as VP of Sales Medical. This move comes as the company sees increasing interest in its CompuFlo® Epidural Instrument and CathCheck™ System, driven by hospitals reopening to sales personnel. Milestone previously paused sales expansion during the pandemic to conserve capital but is now aggressively hiring, growing the sales team to 10 representatives. Trechock brings over 25 years of medical device sales experience, notably increasing annual sales for Flowonix Medical.
Milestone Scientific (NYSE: MLSS) has been invited to present at the virtual Summer Solstice – Best Ideas from the Buy-Side conference, scheduled for June 1-4, 2021. CEO Arjan Haverhals will present on June 2 at 2:00 PM ET and engage in one-on-one meetings with investors during the event. The presentation can be streamed live and is available for replay. The conference features top buy-side recommendations and aims to showcase innovative companies. Milestone specializes in advanced injection technologies aimed at painless and precise drug delivery.
FAQ
What is the current stock price of Milestone Scient (MLSS)?
What is the market cap of Milestone Scient (MLSS)?
